Biopharma's Battle With Scope 3 Emissions

Biopharmaceutical organizations are making strides in reducing their direct emissions, but addressing Scope 3 requires more innovative and effective approaches across the entire value chain.

Scope 3 emissions are particularly complex, as they encompass emissions generated throughout the vast biopharma value chain, including those from suppliers. According to Cytiva's 2024 Global Biopharma Sustainability Review, while companies are effectively managing Scope 1 and 2 emissions, tackling Scope 3 remains a significant hurdle.

Given the numerous stakeholders involved in a product's lifecycle, the limited direct control companies have, and the various challenges that arise, how can biopharma organizations effectively measure and manage this critical aspect of sustainability?